The FDA approved a molecularly targeted therapeutic for treating certain patients with some rare cancers affecting the gastrointestinal system. The U.S. Food and Drug Administration (FDA) has approved the molecularly targeted therapeutic fam-trastuzumab deruxtecan-nxki (Enhertu) to treat adult...
African American men are more likely to feel regret about prostate cancer treatment decisions, and more news of the week from Cancer Today.
The FDA approved a molecularly targeted therapeutic to treat certain pediatric patients and young adults with anaplastic large-cell lymphoma, a rare form of non-Hodgkin lymphoma.
People are using crowdsourced fundraising to cover cancer care costs, and more news of the week from Cancer Today.
Many of the most common cancers are heralded by premalignant conditions. Treating premalignancy may prove to be the most promising tactic for cancer interception.
Researchers in Japan observe the rare occurrence of a mother passing cancer cells to their child, and more news of the week from Cancer Today.
The FDA approved the first once-a-day pill to lower the levels of testosterone in certain patients with prostate cancer. The U.S. Food and Drug Administration (FDA) has approved the first oral gonadotropin-releasing hormone (GnRH)...
The FDA approved the molecularly targeted therapeutic selinexor to be used in combination with another targeted agent and a synthetic corticosteroid to treat certain patients with multiple myeloma. The U.S. Food and Drug Administration...
In the early 1970s, German virologist Harald zur Hausen, MD, FAACR, defied the dogma that cervical cancer was caused by the herpes simplex virus (HSV). He proposed that another virus—the human papillomavirus (HPV)—could lead to cervical cancer. While his initial studies...
As the year draws to a close, we bring you the final edition of Editors’ Picks for 2020. This monthly roundup features one “must read” article, handpicked by the editors, from each journal issue published by the AACR. Studies highlighted in this post include a review article...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More